Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cidara Thera (NQ: CDTX ) 11.62 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cidara Thera CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX May 16, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Regulatory Compliance Exposures Legal Regulatory CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX May 16, 2024 WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara... Via TheNewswire.com Topics Regulatory Compliance Exposures Legal Regulatory CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX May 14, 2024 From The Rosen Law Firm PA Via GlobeNewswire CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX May 13, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Regulatory Compliance Exposures Legal Regulatory CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX May 13, 2024 WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara... Via TheNewswire.com Topics Regulatory Compliance Exposures Legal Regulatory CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm April 25, 2024 From Bragar Eagel & Squire Via GlobeNewswire CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX April 25, 2024 From The Rosen Law Firm, P.A. Via Business Wire 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science March 23, 2023 From 5AM Venture Management, LLC Via GlobeNewswire Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis March 22, 2023 From Melinta Therapeutics, LLC Via Business Wire Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis January 25, 2023 From Melinta Therapeutics, LLC Via Business Wire Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022 October 17, 2022 From Cidara Therapeutics, Inc. Via GlobeNewswire Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma October 04, 2022 From Cidara Therapeutics, Inc. Via GlobeNewswire Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S. July 27, 2022 From Cidara Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.